Calcium vitamin D3 supplementation in clinical practice: side effect and satisfaction

Maryam Sanaei, Mohammad Banasiri, Gita Shafiee, Mahsa Rostami, Saba Alizad, Mehdi Ebrahimi, Bagher Larijani, Ramin Heshmat, Maryam Sanaei, Mohammad Banasiri, Gita Shafiee, Mahsa Rostami, Saba Alizad, Mehdi Ebrahimi, Bagher Larijani, Ramin Heshmat

Abstract

Background: The objective of this study was to assess side effects and satisfaction about OsteoCalVitFort (500 mg calcium and 400 I.U. of vitamin D3) usage.

Methods: A total 186 people were participated with range age from 18 to 65 years old. Each participant received 1 pack that contains 60 OsteoCalVitFort tablet and used two tablet OsteoCalVitFort daily (1 tablet after breakfast and 1 after dinner). By a phone call, side effects and satisfaction about OsteoCalVitFort were assessed.

Results: The rate of constipating (8.0 %) and bloating (12.5 %) were decreased significantly after OsteoCalVitFort supplement intake (1.2 %, and 0.6 %, respectively). Similar results were observed in metallic taste in mouth, tiredness, weakness, loss of appetite, bone/muscle pain and mental/mood change after Calcium Vitamin D3 supplementation intake. Totally, 94 % of patients were satisfied about OsteoCalVitFort usage.

Conclusion: The results of the research indicate despite the high quality of OsteoCalVitFort supplement, there are no side effects which have been seen in other supplements.

Keywords: Calcium; Side effect; Vitamin D.

References

    1. Heaney RP. Calcium, dairy products and osteoporosis. J Am Coll Nutr. 2000;19(sup2):83S–99S. doi: 10.1080/07315724.2000.10718088.
    1. Fleming KH, Heimbach JT. Consumption of calcium in the US: food sources and intake levels. J Nutr. 1994;124(8 Suppl):1426S–30S.
    1. Swagerty D, Jr, Walling A, Klein R. Lactose intolerance. Am Fam Physician. 2002;65(9):1845.
    1. Bayless TM, Rosensweig NS. A racial difference in incidence of lactase deficiency: a survey of milk intolerance and lactase deficiency in healthy adult males. JAMA. 1966;197(12):968–72. doi: 10.1001/jama.1966.03110120074017.
    1. Heyman MB. Lactose intolerance in infants, children, and adolescents. Pediatrics. 2006;118(3):1279–86. doi: 10.1542/peds.2006-1721.
    1. Riggs BL, O'Fallon WM, Muhs J, O'Connor MK, Kumar R, Melton LJ. Long-term effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women. J Bone Miner Res. 1998;13(2):168–74. doi: 10.1359/jbmr.1998.13.2.168.
    1. Bouillon R, Van Cromphaut S, Carmeliet G. Intestinal calcium absorption: molecular vitamin D mediated mechanisms. J Cell Biochem. 2003;88(2):332–9. doi: 10.1002/jcb.10360.
    1. Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P. Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab. 2007;92(4):1415–23. doi: 10.1210/jc.2006-1404.
    1. Nicolaysen R. Studies upon the mode of action of vitamin D: the influence of vitamin D on the absorption of calcium and phosphorus in the rat. Biochem J. 1937;31(1):122. doi: 10.1042/bj0310122.
    1. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet. 2007;370(9588):657–66. doi: 10.1016/S0140-6736(07)61342-7.
    1. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997;337(10):670–6. doi: 10.1056/NEJM199709043371003.
    1. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritisA randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1996;125(12):961–8. doi: 10.7326/0003-4819-125-12-199612150-00004.
    1. Ray NF, Chan JK, Thamer M, Melton LJ. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12(1):24–35. doi: 10.1359/jbmr.1997.12.1.24.
    1. Cummings SR, Kelsey JL, Nevitt MC, O'DOWD KJ. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev. 1985;7(1):178–208.
    1. Kanis J, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A. Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone. 2000;27(5):585–90. doi: 10.1016/S8756-3282(00)00381-1.
    1. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009;301(5):513–21. doi: 10.1001/jama.2009.50.
    1. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int. 2005;16(2):S3–S7. doi: 10.1007/s00198-004-1702-6.
    1. Bagheri P, Haghdoost A-A, Dortaj E, Halimi L, Vafayi Z, Farhangnia M, et al. Ultra analysis of prevalence of osteoporosis in Iranian women a systematic review and meta-analysis. Iran J Endocrinol Metab. 2011;13(3):315–325.
    1. Lloyd T, Andon MB, Rollings N, Martel JK, Landis JR, Demers LM, et al. Calcium supplementation and bone mineral density in adolescent girls. JAMA. 1993;270(7):841–4. doi: 10.1001/jama.1993.03510070063037.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir